Last updated: June 4, 2026
HEMANGEOL supplier landscape (who makes what for the oral solution of Propranolol)
HEMANGEOL is a brand of propranolol oral solution (propranolol hydrochloride) for pediatric infantile hemangioma. Supplier risk is concentrated in (1) propranolol drug substance, (2) oral solution formulation and filling, and (3) packaging components (bottles, closures, child-resistant systems) sourced through contract manufacturing and supply chains.
What companies supply the drug substance and intermediates for HEMANGEOL (propranolol hydrochloride)?
HEMANGEOL’s supply chain is built around generic-capable propranolol hydrochloride manufacturing, with the brand-specific differentiation occurring at the oral solution formulation and finished-dose packaging stage.
Drug substance inputs that shape supplier choices
Key raw materials and intermediates typically include:
- Propranolol free base and/or propranolol hydrochloride synthesis starting materials
- Reagent-grade acids/bases used in salt formation (hydrochloride)
- Solvents and purification aids used to meet pharmacopeial impurities
- Bulk water quality used in final salt preparation steps
Common supplier model for propranolol brands
Propranolol hydrochloride is widely available from multiple bulk manufacturers. Brand suppliers usually manage risk by qualifying at least two sources for:
- Drug substance (API) lots
- Key excipients that affect solubility and shelf-life in an oral solution matrix
- Critical packaging components that drive container closure integrity
Who manufactures the finished HEMANGEOL oral solution (formulation, filling, and packaging)?
Supplier responsibility for HEMANGEOL concentrates at the contract manufacturing and packaging layer:
- Oral solution compounding (mixing and solubilization)
- In-process controls for pH, clarity/particulates, and microbial limits
- Filtration/sterilizing strategy consistent with oral non-sterile or sterile design (depends on registered process)
- Fill-finish into dropper or measuring-cap enabled bottles
- Packaging line execution with child-resistant closures and tamper evidence
What to look for in supplier qualification
For an oral solution brand, qualification typically requires:
- Ability to replicate viscosity, clarity, and pH specifications across commercial scale
- Stability-indicating analytical control packages
- Batch record and validation history aligned to marketed shelf life
- Supply continuity for closure systems and delivery devices
Which excipient and packaging suppliers are most likely involved in HEMANGEOL?
While propranolol is the active, an oral solution depends heavily on excipients and packaging-grade performance.
Excipients that typically drive supplier switching risk
For propranolol oral solutions, excipient supply commonly includes:
- Aqueous base with buffering components to control pH
- Solubilizers/co-solvents to maintain clarity and reduce precipitation
- Viscosity-modifying agents where required for dosing uniformity
- Preservatives or antimicrobial systems where included
- Sweeteners/flavorants used to support pediatric adherence (supply constraints can be material)
Packaging components that can constrain supply
- Bottle material and coating compatibility (adsorption and extractables/leachables risk)
- Closure material and liner chemistry for container closure integrity
- Dropper or dosing device compatibility with bottle thread finish and volume tolerances
How do HEMANGEOL supply-chain suppliers differ by geography (US vs EU/UK)?
Supplier configuration tends to diverge where:
- Manufacturing site geography differs from marketing authorization holder responsibilities
- Regulatory release testing (batch release) is performed locally versus centralized
- Importation and cold-chain requirements (if any) add logistics complexity
For propranolol oral solutions, supply chains are usually structured around:
- One primary fill-finish site with additional secondary capacity qualified for continuity
- Regional importers/distributors for commercial distribution
- Local distributors aligned with pharmacovigilance and complaint handling
What patent and regulatory factors affect supplier eligibility for HEMANGEOL manufacturing?
Even when API supply is commodity-like, supplier eligibility is affected by:
- Process and formulation IP for the specific oral solution composition and manufacturing process
- Brand-specific registered parameters that constrain equivalent process changes
- Regulatory expectations for comparability across scale-up and tech transfer
How IP maps to supplier barriers
- Drug substance IP: generally weaker for mature propranolol but can still matter if specific intermediates or process conditions are claimed.
- Formulation and process IP: can block straightforward “make a similar solution” approaches.
- Packaging/labeling: not typically IP-heavy, but can be tied to registered product presentations and dosing devices.
Key Takeaways
- HEMANGEOL supply is dominated by contract fill-finish and packaging qualification layered on top of broadly available propranolol hydrochloride API supply.
- The main supplier risk points are oral solution formulation controls, container-closure systems, and pediatric dosing device compatibility.
- Supplier switching in HEMANGEOL is constrained less by propranolol availability and more by registered formulation/process performance and packaging integrity requirements.
FAQs
-
Is HEMANGEOL API sourced globally or from a single propranolol hydrochloride supplier?
Typically multi-sourced at the API level to ensure continuity, with brand-specific controls implemented downstream at the finished-dose stage.
-
Can generic propranolol oral solutions be substituted for HEMANGEOL without supply-chain requalification?
Substitution depends on whether the product is registered as therapeutically equivalent and meets presentation, formulation, and dosing delivery requirements.
-
What supply constraints most often impact pediatric oral solution brands like HEMANGEOL?
Closure systems, dosing devices, and any excipients required for clarity/stability are common constraints.
-
Does HEMANGEOL require sterile manufacturing?
The manufacturing design (sterile vs non-sterile) depends on the registered product specifications and approved process controls.
-
What matters more for supplier qualification: API or the finished oral solution fill-finish?
For a brand oral liquid, fill-finish and formulation performance usually drives the practical qualification and continuity plan.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book).
- EMA. Public assessment reports and product information for propranolol-containing medicinal products for infantile hemangioma. European Medicines Agency.
- DailyMed. HEMANGEOL (propranolol hydrochloride) label and prescribing information. U.S. National Library of Medicine.
